SANA

Sana Biotechnology, Inc. | Cotação de Ações

Última atualização19/09/2025, 17:00:00

PreçoUS$ 3,09

Variação (dia)-US$ 0,20 (-6.08%)▼

Min. 52 SemanasUS$ 1,26

Máx. 52 SemanasUS$ 7,30

Capitalização de mercado--

Endereço: 188 East Blaine Street, Seattle, WA, 98102

Telefone: 206 701 7914

Funcionários: 194

Sana Biotechnology, Inc.SANA

US$ 3,09

- 0,26,1%

19/09/2025 17:00:00

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 3,09

Valor de mercado--

AberturaUS$ 3,31

Preço máximoUS$ 3,35

Preço mínimoUS$ 3,07

VolumeUS$ 13 mi

Fechamento anteriorUS$ 3,29

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Ações relacionadas

Verve Therapeutics, Inc.

VERV ▼0.37% | US$ 7,39

Vor Biopharma Inc.

VOR ▼0.04% | US$ 1,35

Nkarta, Inc.

NKTX ▼0.09% | US$ 2,34

C4 Therapeutics, Inc.

CCCC ▲0.03% | US$ 3,65

Relay Therapeutics, Inc.

RLAY ▼0.04% | US$ 4,68

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Saiba mais sobre a brapi e nossa missão de fornecer informações confiáveis

Entenda a missão da brapi em fornecer informações estritamente informativas de fontes confiáveis. Valorizamos a transparência e a responsabilidade, incentivando investidores a buscar aconselhamento financeiro independente para decisões informadas.

Acesse a Documentação para uma compreensão detalhada da nossa plataforma

Explore a Documentação para uma compreensão detalhada de como utilizar efetivamente nossa plataforma para análise de investimentos. Oferecemos recursos abrangentes para orientar investidores, desde iniciantes até experientes, na navegação por nossa plataforma.